BIOMARIN PHARMACEUTICAL INC
For the period ended Nov 2, 2026. Filed Nov 2, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 2, 2026 · Filed Nov 2, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Value Commitment
Value Commitment
BioMarin continued to integrate Amicus in the third quarter, realizing accelerated cost synergies to enable investments in initiatives to drive future growth of GALAFOLD and POMBILITI + OPFOLDA. BioMarin continues to expect approximately $280 million of GAAP cost synergies (approximately $220 million on a Non-GAAP basis) to be fully realized in 2028.
On August 30, 2026, the company announced the global settlement of all outstanding claims with Ascendis Pharma A/S related to its product Yuviwel. As part of the agreement, Ascendis will pay BioMarin a royalty equal to 20% of net sales of Yuviwel in the U.S., retroactive to the first commercial sale, and 18% of net sales in the European Union, Brazil and South Korea until May 2030.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.